Abstract
Genetic variations in drug-induced liver injury (DILI): resolving the puzzle
Highlights
There are discrepancies in the findings and many studies are based on small cohorts and subsequently insufficient to confirm a prominent association between genetic variability in drug metabolism and the risk of drug-induced liver injury (DILI)
A range of studies have identified a number of genetic variants in drug metabolism Phase I, II, and III genes, including cytochrome P450 (CYP) 2E1, N-acetyltransferase 2, UDP-glucuronosyltransferase 2B7, glutathione S-transferase M1/T1, ABCB11, and ABCC2, that enhance DILI susceptibility (Andrade et al, 2009; Agundez et al, 2011)
There are discrepancies in the findings and many studies are based on small cohorts and subsequently insufficient to confirm a prominent association between genetic variability in drug metabolism and the risk of DILI
Summary
There are discrepancies in the findings and many studies are based on small cohorts and subsequently insufficient to confirm a prominent association between genetic variability in drug metabolism and the risk of DILI. A range of studies have identified a number of genetic variants in drug metabolism Phase I, II, and III genes, including cytochrome P450 (CYP) 2E1, N-acetyltransferase 2, UDP-glucuronosyltransferase 2B7, glutathione S-transferase M1/T1, ABCB11, and ABCC2, that enhance DILI susceptibility (Andrade et al, 2009; Agundez et al, 2011).
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.